Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States
: In newly diagnosed stage III/IV classic Hodgkin lymphoma (cHL), A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) improved overall survival (OS) versus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). As clinical trial and real-world populations may differ, real-world treatment characteristics and OS (rwOS) were assessed for patients with stage III/IV cHL treated with frontline ABVD.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Allison Winter, Nicholas Liu, Andy Surinach, Michelle Fanale, Kristina S. Yu, Mayur Narkhede Tags: Original Study Source Type: research
More News: Clinical Trials | Databases & Libraries | Hematology | Leukemia | Lymphoma | Myeloma | Study | USA Health